Summary
Johnson & Johnson reported strong sales growth in its first quarter of 2008, with total sales reaching $16.2 billion, a 7.7% increase year-over-year. This growth was driven by robust performance across its Consumer and Medical Devices & Diagnostics segments, while the Pharmaceutical segment saw modest growth, impacted by generic competition for key drugs like Risperdal. Net earnings saw a significant increase to $3.6 billion, up from $2.6 billion in the prior year's first quarter, leading to a substantial rise in diluted earnings per share from $0.88 to $1.26. This improved profitability was partly due to the absence of a large in-process research and development charge that impacted the prior year's results. The company also demonstrated strong cash flow generation from operations, providing ample liquidity for strategic investments and shareholder returns, including a recent dividend increase.
Key Highlights
- 1Total sales increased by 7.7% to $16.2 billion, with international sales showing a stronger growth rate of 13.7% compared to U.S. sales growth of 2.8%.
- 2Net earnings significantly increased to $3.6 billion from $2.6 billion in the prior year, boosted by higher sales and the absence of a large IPR&D charge from the prior year's acquisition.
- 3Diluted earnings per share rose to $1.26 from $0.88 in the prior year's first quarter.
- 4The Consumer segment experienced a strong 16.2% sales increase, particularly driven by the OTC Pharmaceuticals & Nutritionals franchise.
- 5The Medical Devices & Diagnostics segment also showed healthy growth with a 7.2% increase in sales, led by strong performance in DePuy and Ethicon Endo-Surgery.
- 6Pharmaceutical segment sales grew by 3.3%, though this was impacted by generic competition for drugs like Risperdal and Duragesic, partially offset by strong growth in REMICADE and CONCERTA.
- 7The company continued its commitment to shareholder returns, declaring an increased quarterly dividend and actively repurchasing shares.